Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr 3]octreotate

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 4, 2008, Pages 749-755

  De Keizer, Bart ^a   Van Aken, Maarten O ^a   Feelders, Richard A ^a   De Herder, Wouter W ^a   Kam, Boen L R ^a   Van Essen, Martijn ^a   Krenning, Eric P ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Carcinoid crisis; Lu 177 octreotate; Neuroendocrine tumors; Peptide receptor radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ARGININE; BISOPROLOL; CATECHOLAMINE; CHROMOGRANIN A; CORTICOSTEROID; HORMONE; HORMONE RECEPTOR; LOPERAMIDE; LUTETIUM 177; LYSINE; METOCLOPRAMIDE; MORPHINE; NORMETADRENALIN; NUCLEOTIDE; OCTREOTATE LU 177; OCTREOTIDE; PHENTOLAMINE; POTASSIUM; SOMATOSTATIN DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE METASTASIS; BRONCHUS CARCINOID; CARCINOID; CARDIOMYOPATHY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG UPTAKE; EMOTIONAL STRESS; FEMALE; FLUSHING; HEART MUSCLE ISCHEMIA; HORMONE RELEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; ISOTOPE LABELING; LIVER METASTASIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PHEOCHROMOCYTOMA; SHOCK; SIDE EFFECT; STOMACH CARCINOID; TUMOR CELL DESTRUCTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ENDOCRINE SYSTEM DISEASES; GASTROINTESTINAL NEOPLASMS; HUMANS; LUTETIUM; MIDDLE AGED; NEUROECTODERMAL TUMORS, PRIMITIVE; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; RADIOISOTOPES; RETROSPECTIVE STUDIES;

EID: 40949149404     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0691-z     Document Type: Article

References (23)

1. Karmy-Jones R, Vallieres E. Carcinoid crisis after biopsy of a bronchial carcinoid. Ann Thorac Surg. 1993;56:1403-5.
2. Kharrat HA, Taubin H. Carcinoid crisis induced by external manipulation of liver metastasis. J Clin Gastroenterol. 2003;36:87-8.
3. Ozgen A, Demirkazik FB, Arat A, Arat AR. Carcinoid crisis provoked by mammographic compression of metastatic carcinoid tumour of the breast. Clin Radiol. 2001;56:250-1.
4. Vaughan DJA, Brunner MD. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin. 1997;35:129-42.
5. Salm EF, Janssen M, Breburda CS, van Woerkens LJPM, de Herder WW, Zwaan Cvd, et al. Carcinoid crisis during transesophageal echocardiography. Intensive Care Med. 2000;26:254-54.
6. Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem. 2003;40:612-27.
7. Davi MV, Bodei L, Francia G, Bartolomei M, Oliani C, Scilanga L, et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest. 2006;29:563-7.
8. Kaltsas GA, Papadogias D, Grossman AB. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res. 2004;31:61-75.
9. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-62.
10. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28:1319-25.
11. Bloom SR, Yiangou Y, Polak JM. Vasoactive intestinal peptide secreting tumors. Pathophysiological and clinical correlations. Ann N Y Acad Sci. 1988;527:518-27.
12. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet. 1998;352:799-805.
13. Kizer JR, Koniaris LS, Edelman JD, St. John Sutton MG. Pheochromocytoma crisis, cardiomyopathy, and hemodynamic collapse. Chest. 2000;118:1221-3.
14. Werbel SS, Ober KP. Pheochromocytoma. Update on diagnosis, localization, and management. Med Clin North Am. 1995;79:131-53.
15. Sasaki M, Iwaoka T, Yamauchi J, Tokunaga H, Naomi S, Inoue J, et al. A case of Sipple's syndrome with malignant pheochromocytoma treated with 131I-metaiodobenzyl guanidine and a combined chemotherapy with cyclophosphamide, vincristine and dacarbazine. Endocr J. 1994;41:155-60.
16. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003;134:956-62.
17. Bell HK, Poston GJ, Vora J, Wilson NJ. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005;152:71-5.
18. Frojd C, Larsson G, Lampic C, von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18.
19. Rolleman EJ, Kooij PP, de Herder WW, Valkema R, Krenning EP, de Jong M. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging 2007;34(11):1854-60.
20. de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol. 2002;14:53-7.
21. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-73.
22. Kvols LK, Martin JK, Marsh HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med. 1985;313:1229-30.
23. Warner RR, Mani S, Profeta J, Grunstein E. Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med. 1994;61:349-55.